177Lu-Labeled RGD-BBN Peptide for Targeting Prostate Cancer
Over the past two decades, peptide receptor radionuclide therapy (PRRT) has been developed as a valid approach for cancer adjuvant treatment. 177Lu is an excellent radionuclide suitable for radionuclide therapy of tumors and metastases, which highlights the advantages of using PRRT for cancer treatment, subsequently encourages scientists to explore many different types of peptides for tumor radionuclide therapy. Arg-Gly-Asp (RGD) and bombesin (BBN) heterodimers have been investigated for dual targeting of tumor integrin αvβ3 receptors and gastrin-releasing peptide receptors. In this chapter, we present the potential application of 177Lu-labeled RGD-BBN heterodimer for targeting prostate cancer.
Keywords:Gastrin-releasing peptide receptor Integrin αvβ3 177Lu RGD-bombesin Prostate cancer
This work was supported by DOD-PCRP-NIA PC094646 and sponsored by Shanghai Pujiang Program. The production of 177Lu was supported by Department of Energy Grant 84900-001-10.